DASL HiCaP

About this trial

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Patient Profile

Where’s this trial being run?

Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre, St Luke’s Hospital, Mater Misericordiae University Hospital, and Mater Private Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: DASL HiCaP
Number: CTRIAL-IE 19-32
Full Title:

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.

Principal Investigator: Prof Ray McDermott
Type: Collaborative
Sponsor:

EU Sponsor- Cancer Trials Irelamd
Global Sponsor-University Of Sydney

Recruitment Started: Global: March 2021
Ireland: 7th July 2021
Global Recruitment Target: 1100
Ireland Recruitment Target: 200